WilmerHale Reps Eleven Biotherapeutics in License Agreement with Roche for Antagonist Antibody Technology

WilmerHale Reps Eleven Biotherapeutics in License Agreement with Roche for Antagonist Antibody Technology

Firm News

WilmerHale represented Eleven Biotherapeutics, a biopharmaceutical company researching and developing protein therapeutics to treat diseases of the eye, in the negotiation of a license agreement with Roche for Eleven's IL-6 antagonist monoclonal antibody program, including its preclinical ophthalmic drug EBI-031.

The agreement was signed in June; its effectiveness is subject to approval by Eleven's stockholders. Assuming such approval is obtained, Eleven would be entitled to a $7.5 million upfront, and up to $262.5 million in future milestone, plus royalties.

The WilmerHale team consisted of Partner Belinda Juran and Associates Alex Civetta and Ritu Gupta on the license agreement, and Partners Brian Johnson and Hal Leibowitz and Counsel Chris Barnstable-Brown leading the corporate matters.

Read Eleven Biotherapeutics' press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.